New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
10:27 EDTCANFCan-Fite CF102 approved for compassionate use in Israel
Can-Fite BioPharma announced that the Israeli Ministry of Health has approved the use of its drug CF102 for a patient with hepatocellular carcinoma, the most common form of liver cancer, under the country's Compassionate Use Program. The program allows doctor-initiated single-patient access to investigational treatments for innovative or investigational products not yet registered in any country worldwide. Can-Fite has also previously received Orphan Drug Designation from the U.S. FDA for CF102 in the treatment of advanced hepatocellular carcinoma.
News For CANF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
06:43 EDTCANFCan-Fite BioPharma to host special shareholder meeting
Subscribe for More Information
December 15, 2014
07:16 EDTCANFCan-Fite says second part of Phase II glaucoma study approved in Bulgaria
Subscribe for More Information
December 9, 2014
07:06 EDTCANFCan-Fite BioPharma to initiate development program of CF602
Can-Fite BioPharma reported that it will initiate a pre-clinical development program of its next generation drug CF602 for the indication of sexual dysfunction. Upon successful completion, the company intends to file an IND with the FDA to allow human Phase I studies. Can-Fite reports that it received positive pre-clinical data conducted in experimental animal models demonstrating that CF602 has improved sexual dysfunction in a dose dependent manner. CF602 is a novel A3 adenosine receptor allosteric modulator, enhancing the affinity of the natural ligand adenosine to its A3 adenosine receptor.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use